The nonstructural 5A protein of hepatitis C virus genotype 1b does not contain an interferon sensitivity-determining region

Journal of Infectious Diseases

Volumn 195, Issue 3, 2007, Pages 432-441

  Brillet, Rozenn ^a   Penin, François ^c   Hezode, Christophe ^a,b   Chouteau, Philippe ^a   Dhumeaux, Daniel ^a,b   Pawlotsky, Jean Michel ^a,b  

^a INSERM   (France)

^b HENRI MONDOR HOSPITAL   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; NONSTRUCTURAL PROTEIN 5A; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; AGED; AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; DRUG SENSITIVITY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENY; PRIORITY JOURNAL; UNINDEXED SEQUENCE; VIRUS INHIBITION;

EID: 33846450647     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/510316     Document Type: Article

References (43)

1. National Institutes of Health. National Institutes of Health Consensus Development Conference statement: management of hepatitis C: 2002-June 10-12, 2002. Hepatology 2002; 36:53-20.
2. Pawlotsky JM. Therapy of hepatitis C: from empiricism to eradication. Hepatology 2006; 43:5207-20.
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-65.
6. Pawlotsky JM. Mechanisms of antiviral treatment efficacy and failure in chronic hepatitis C. Antiviral Res 2003; 59:1-11.
7. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Semin Liver Dis 2005; 25:72-83.
8. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b: sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96:224-30.
9. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81.
10. Pascu M, Martus P, Hohne M, et al. Sustained virological response in hepatitis C virus type 1b infected patients is predicted by the number of mutations within the NS5A-ISDR: a meta-analysis focused on geographical differences. Gut 2004; 53:1345-51.
11. Neumann AU, Lam NP, Dahari H, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science 1998; 282:103-7.
12. Neumann AU, Zeuzem S, Ferrari C, et al. Ditto-HCV early viral kinetics report: novel decline patterns in genotype 1 but not genotypes 2 and 3 patients treated with peg-interferon alfa-2a and ribavirin. J Hepatol 2002; 36(Suppl 1):121.
13. Herrmann E, Lee HJ, Marinos G, Modi M, Zeuzem S. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon. Hepatology 2003; 37:1351-8.
14. Bain V, Kaita K, Yoshida E, et al. A phase 2 study to assess antiviral response, safety, and pharmacokinetics of albuferon in IFN-alpha naive subjects with genotype 1 chronic hepatitis C. J Hepatol 2005; 42(Suppl 2):9.
15. Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004; 126:703-14.
16. Thompson JD, Higgins DG, Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 1994; 22:4673-80.
17. Combet C, Penin F, Geourjon C, Deleage G. HCVDB: hepatitis C virus sequences database. Appl Bioinformatics 2004; 3:237-40.
18. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci USA 1990; 87:9524-8.
19. Combet C, Blanchet C, Geourjon C, Deleage G. NPS@: network protein sequence analysis. Trends Biochem Sci 2000; 25:147-50.
20. Polyak SJ. Hepatitis C virus-cell interactions and their role in pathogenesis. Clin Liver Dis 2003; 7:67-88.
21. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. J Gen Virol 2004; 85:2485-502.
22. Layden-Almer JE, Kuiken C, Ribeiro RM, et al. Hepatitis C virus genotype 1a NS5A pretreatment sequence variation and viral kinetics in African American and white patients. J Infect Dis 2005; 192:1078-87.
23. Aus dem Siepen M, Lohmann V, Wiese M, Ross S, Roggendorf M, Viazov S. Nonstructural protein 5A does not contribute to the resistance of hepatitis C virus replication to interferon alpha in cell culture. Virology 2005; 336:131-6.
24. Sarrazin C, Herrmann E, Bruch K, Zeuzem S. Hepatitis C virus nonstructural 5A protein and interferon resistance: a new model for testing the reliability of mutational analyses. J Virol 2002; 76:11079-90.
25. Nousbaum J, Polyak SJ, Ray SC, et al. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol 2000; 74:9028-38.
26. Gale M Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18:5208-18.
27. Gale M Jr, Kwieciszewski B, Dossett M, Nakao H, Katze MG. Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol 1999; 73:6506-16.
28. Polyak SJ, Khabar KS, Paschal DM, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001; 75:6095-106.
29. Polyak SJ, Khabar KS, Rezeiq M, Gretch DR. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol 2001; 75:6209-11.
30. He Y, Nakao H, Tan SL, et al. Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol 2002; 76:9207-17.
31. Macdonald A, Crowder K, Street A, McCormick C, Saksela K, Harris M. The hepatitis C virus non-structural NS5A protein inhibits activating protein-1 function by perturbing ras-ERK pathway signaling. J Biol Chem 2003; 278:17775-84.
32. Tan SL, Nakao H, He Y, et al. NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. Proc Natl Acad Sci USA 1999; 96:5533-8.
33. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436:939-45.
34. Pawlotsky JM, Hezode C, Pellegrin B, et al. Early HCV genotype 4 replication kinetics during treatment with peginterferon alpha-2a (Pegasys)-ribavirin combination: a comparison with HCV genotypes 1 and 3 kinetics. Hepatology 2002; 36:291A.
35. Blindenbacher A, Duong FH, Hunziker L, et al. Expression of hepatitis C virus proteins inhibits interferon alpha signaling in the liver of transgenic mice. Gastroenterology 2003; 124:1465-75.
36. Heim MH, Moradpour D, Blum HE. Expression of hepatitis C virus proteins inhibits signal transduction through the Jak-STAT pathway. J Virol 1999; 73:8469-75.
37. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science 1999; 285:107-10.
38. Foy E, Li K, Sumpter R Jr, et al. Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci USA 2005; 102:2986-91.
39. Foy E, Li K, Wang C, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science 2003; 300:1145-8.
40. Li K, Foy E, Ferreon JC, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIP. Proc Natl Acad Sci USA 2005; 102:2992-7.
41. Loo YM, Owen DM, Li K, et al. Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci USA 2006; 103:6001-6.
42. Chen L, Borozan I, Feld J, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005; 128:1437-44.
43. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006; 131:1040-8.